This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Gilead patent partially upheld by EPO, Teva and STADA's challenge continues

( April 14, 2025, 15:38 GMT | Official Statement) -- MLex Summary: The European Patent Office's Technical Board of Appeal has partially upheld Gilead Sciences Inc’s EP 3,150,586, which covers compounds that enhance the performance of other drugs. The board revoked certain claims of the patent, but found other claims to be legally sound. The case has been remitted for further review, with generic companies Teva and STADA remaining in opposition, as the patent's final validity is still under dispute.See EPO decision attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections